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Abstract 
Rhesus (Rh) alloimmunization is potentially 
devastating for reproductive health. Rarely, RhD 
mismatched blood may be transfused 
accidentally, increasing the risks of RhD 
sensitization. Prevention of Rh sensitization is 
important especially in women of reproductive 
age group. Treatment with intravenous RhIg is 
potentially safe and also the effective means of 
preventing Rh alloimmunization in cases of Rh-
mismatched blood transfusion. We report a case 
that illustrates the significantly high RhD 
antibody titers following treatment with 
intravenous Rh immunoglobulin for prevention of 
alloimmunization. An 18yo Rh-negative G0 had 
mistakenly received four units of Rh-positive 
blood.  To avoid future pregnancy related 
complications, she received monotherapy with 
13,200 μg total of intravenous Rh 
immunoglobulin (RhIg). The treatment was well 
tolerated; however the RhD antibody titers 
reached a peak of 1:512. The high levels of RhD 
antibody titers can have grave implications if the 
patient is pregnant. 
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Introduction 
Alloimmunization in most obstetric 
cases occurs after transplacental 
passage of fetal blood into the maternal 
system during pregnancy-related 
causes or events. Rarely can it occur 
following RhD mismatched blood 
transfusion. The incidence of 
mismatched transfusion is quoted to be 
approximately 1 in 100,000 US 
population.  In 2008, a total of 165 
incompatible blood transfusions were 
reported in the United States community 
hospitals.1  
Prevention of alloimmunization in 
women of reproductive age is of utmost 
importance to avoid future pregnancy 
complications.  In cases of RhD 
mismatched blood transfusion, the 
suggested treatments include red blood 
cell exchange transfusion and 
administration of intravenous (IV) rhesus 
immune globulin (RhIg) within 72 hours.  
Described here is a case of RhD 
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mismatched transfusion and treatment 
with only intravenous rhesus immune 
globulin (WinRho SD, NABI, Boca 
Raton, FL). The treatment was 
associated with significant, but transient 
elevations in Rh anti D antibody titers.      
Case Report 
An 18-year-old nulligravid woman was 
involved in a high-speed motor vehicle 
accident and was found to be unstable 
with a blood pressure of 76/38 mm Hg.  
The initial work-up revealed extensive 
internal injuries and several fractures, as 
well as a small subdural hematoma.  
The patient emergently received four 
units of RhD positive blood. Following 
the transfusion, it was realized that the 
patient was RhD negative. 
The implications of RhD incompatibility 
for future pregnancies were discussed 
with the patient.  Intramuscular (IM) 
RhIg was determined to be impractical 
because of the large volumes needed.  
The option of red blood cell exchange 
transfusion was considered, though with 
a delay, due to concerns of increasing 
the intracranial pressure in the presence 
of a subdural hematoma. The patient 
and her family decided against the 
exchange transfusion for fear of 
complications. Due to the critical 
condition of the patient, the obstetrical 
team was consulted only fourteen days 
after admission regarding the 
implications of RhD sensitization in a 
woman of reproductive age group. The 
patient was counseled about obstetrical 
risks associated with RhD 
alloimmunization, and was offered 
treatment with intravenous (IV) RhIg.  
She decided in favor of this treatment. 
 
The dose of RhIg was calculated based 
on the amount of RhD mismatched 
blood transfused.  The patient had 
received 1200 cc of blood. With a 55% 
hematocrit, that is equivalent to an 
exposure of 660 ccs of Rh positive red 
blood cells.  The total dose of IV RhIg 
(dosed at 90 IU of IV RhIg per 1 mL of 
mismatched PRBCs) was calculated at 
59,400 IU for our patient. Since the 
maximum daily dose of the IV RhIg 
advised is 3000 IU every 8 hours, we 
gave the total dose over a seven day 
period to ensure adequate treatment. 
RhD antibody titers were obtained daily 
during this treatment, and repeated 
monthly after discharge. The patient 
tolerated the treatment well and did not 
show any signs of overt jaundice or 
renal complications, and did not require 
any blood transfusion. The anti RhD 
antibody titers rose to a peak of 1:512, 
dropping to 1:8 at the end of the 3rd 
month. Even with the high RhD antibody 
titers, serum bilirubin levels remained 
below 2mg/ dl. [Figure 1]  Follow up 
titers were not available after the 3rd 
month.  
Discussion 
The reported rate of mismatched blood 
transfusion is approximately 1 per 
12,000 units2 and the complications of 
which are multiple.  Factors such as 
amount of mismatched blood received 
and immune status contribute to the 
likelihood of RhD alloimmunization, 
which is approximately 80% after 
transfusion with 500 cc of RhD 
mismatched blood.3   After the first 
exposure to RhD antigen, antibodies 
may not be detectable for at least 4 
weeks.4 
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In a mismatched blood transfusion, a 
red blood cell exchange transfusion or 
RhIg injection has been used 
successfully for prevention of RhD 
sensitization. The mechanism by which 
the RhIg inhibits sensitization is 
hypothesized to be by antigen clearance 
or by alteration of antigen processing 
and presenting.5  
 
 
Figure 1: Anti D antibody titer and total bilirubin levels following administration of 
intravenous RhIg 
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When the volume of the inappropriate 
blood transfused is large, a combination 
of exchange transfusion and IV RhIg 
has been proposed.6 Nester, et al 
described two cases where RhD 
negative women received RhD positive 
blood and were successfully treated with 
the combination therapy.6 Both women 
had negative RhD antibody titers six 
months after the treatment.  
Usage of RhIg alone, has been reported 
with success as well as failure which is 
probably dependent on the dosing of the 
RhIg..7,8 Blood volume as low as 0.1 ml 
can lead to Rh sensitization.9 
Inadequacy in the dosing of the RhIg 
could lead to failure of prophylaxis. In 
our case, even though the volume of the 
inappropriate blood transfused was 
large, we decided in favor of IV RhIg 
monotherapy due to the 14 day delay in 
the treatment. The dose of IV RhIg 
administered was large and calculated 
to cover the large volume of the RhD 
mismatched transfused blood, but the 
patient tolerated the treatment well.  
In the previously reported case of 
treatment failure with RhIg alone, the 
patient was given 1,650 μg RhIg, for a 
single unit of RhD inappropriate blood 
transfusion.7 In that case the RhD 
antibody titers were reported to rise to: 
1:8, 1:512, 1:512, and 1:64, on post-
transfusion days 6, 70, 119, and 369 
respectively.  The persistence of 
antibodies more than one year later was 
taken as evidence of treatment failure, 
by the authors.  In our case, following 
treatment with IV RhIg, the antibody 
titers rose significantly but the rise did 
not persist.  By post-transfusion day 91, 
the RhD antibody titers had fallen from 
1:512 to 1:8.  Though we feel reassured 
with the drop in the titers, we cannot 
categorically comment on the long-term 
success of the management since the 
patient was lost to follow up.  
In RhD sensitized pregnancies, RhD 
antibody titer between 1:8 and 1:32 is 
defined as the critical titer, above which 
the RhD positive fetus is at a significant 
risk for fetal hydrops.10 The peak titer 
achieved in our case was 1:512 
following treatment with the IV RhIg, and 
the higher titers persisted over a period 
of 2 months. Though our patient was not 
pregnant, the elevation in the RhD 
antibody titers has implications in a 
pregnant woman carrying an RhD 
positive fetus.  
In recent times, IV RhIg has also been 
used successfully in the treatment of 
immune thrombocytopenic purpura (ITP) 
during pregnancy, the exact mechanism 
of which is not well understood.11,12 RhIg 
demonstrates the ability to block the 
reticuloendothelial system from clearing 
antibody-coated cells, and to also 
modulate the immune system.12 
Management of conditions such as 
mismatched blood transfusion and ITP 
with large doses of RhIg can lead to 
RhD antibody titers rising beyond the 
critical levels and can be potentially 
harmful to the fetus if the patient is 
pregnant. 
Conclusion 
It appears that IV RhIg alone is a safe 
and potentially effective treatment for 
prevention of alloimmunization following 
RhD mismatched blood transfusion, 
even when the volume is large.  In 
cases of RhD mismatched blood 
transfusions, if the treatment is delayed 
beyond 14 days, IV RhIg should still be 
considered as long as the patient has a 
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negative pre-treatment RhD antibody 
titer. However, due to the sharp rise in 
the RhD antibody titers following 
treatment, caution should be exercised 
when considering IV RhIg for treatment 
in pregnant women.   
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